- Investor's Business Daily•4 hours ago
Barclays analyst Geoff Meacham on Thursday said he expected Gilead Sciences' 2017 outlook to be hindered on limited hepatitis C sales.
- Motley Fool•7 hours ago
Bargain-hunters can start off the year by taking a deeper look at these three promising healthcare stocks.
- Barrons.com•8 hours ago
Gilead Sciences (GILD) is scheduled to release earnings on Feb. 7, and expectations from investors are low, very low. In fact, Barclays analyst Geoff Meacham and team contend that what Gilead says about ...
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||71.61 x 200|
|Ask||71.72 x 1000|
|Day's Range||71.23 - 72.25|
|52 Week Range||70.83 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.62|
|Dividend & Yield||1.88 (2.61%)|
|1y Target Est||N/A|